ReviewPharmaceuticals (Basel, Switzerland)2023
Targeted Alpha Therapy: All We Need to Know about
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Folate Receptor Alpha Targeted Immuno-Positron Emission Tomography Probe for Noninvasive Imaging in Triple-Negative Breast Cancer.Chemical & biomedical imaging · 2026Article
- Review
- Salivary glands as the primary dose-limiting organ: an integrated dosimetry, efficacy, and toxicity study ofFrontiers in pharmacology · 2026Article
- Therapeutic evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Towards DFO*Pharmaceutics · 2025Article
- An overview of the role of radionuclides in targeted cancer treatment: application of biomarkers for patient selection and developments to improve treatment efficacy.Frontiers in oncology · 2025Review
- EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment.Theranostics · 2025Article
- Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology.Pharmaceutics · 2024Review
- Advances in targeted alpha therapy of cancer.European journal of nuclear medicine and molecular imaging · 2024Article
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- Actinium-225 in Targeted Alpha Therapy.Journal of medical physicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high energy of α emitters, and the strong linear energy transfer that goes along with it, lead to very efficient cell killing through DNA damage. Moreover, the degree of oxygenation and the cell cycle state have no impact on these effects. Therefore, α radioisotopes can offer a treatment choice to individuals who are not responding to β- or gamma-radiation therapy or chemotherapy drugs. Only a few α-particle emitters are suitable for targeted alpha therapy (TAT) and clinical applications. The majority of available clinical research involves
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.